Galecto Stock Today
| GLTO Stock | USD 27.99 0.00 0.00% |
PerformanceFair
| Odds Of DistressModerate
|
Galecto is selling at 27.99 as of the 2nd of March 2026; that is No Change since the beginning of the trading day. The stock's open price was 27.985. Galecto has over 59 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 2nd of December 2025 and ending today, the 2nd of March 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of October 2020 | Category Healthcare | Classification Health Care |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts. Galecto operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.59 M outstanding shares of which 277 K shares are currently shorted by private and institutional investors with about 0.12 trading days to cover. More on Galecto
Moving against Galecto Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Galecto Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsGalecto utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Galecto's leverage profile, showing how much of Galecto's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||
Galecto (GLTO) is traded on NASDAQ Exchange in USA and employs 5 people. Galecto is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.73 M. Galecto conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.59 M outstanding shares of which 277 K shares are currently shorted by private and institutional investors with about 0.12 trading days to cover.
Galecto currently holds about 79.03 M in cash with (18.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.11.
Check Galecto Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Galecto is $43.73 Million. Galecto retains 3.56 (percent) of its outstanding shares held by insiders and 13.38 (percent) owned by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Galecto Ownership Details
Galecto Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citigroup Inc | 2025-09-30 | 43.0 | |
| Sbi Securities Co Ltd | 2025-09-30 | 18.0 | |
| Susquehanna International Group, Llp | 2025-09-30 | 0.0 | |
| Novo A/s | 2025-12-31 | 0.0 | |
| Renaissance Technologies Corp | 2025-12-31 | 0.0 | |
| Two Sigma Investments Llc | 2025-12-31 | 0.0 | |
| Fmr Inc | 2025-12-31 | 238.9 K | |
| Jain Global Llc | 2025-12-31 | 120.6 K | |
| Boothbay Fund Management, Llc | 2025-12-31 | 95.8 K | |
| Connective Capital Management Llc | 2025-09-30 | 27 K | |
| Vanguard Group Inc | 2025-12-31 | 18.2 K |
Galecto Historical Income Statement
Galecto Stock Against Markets
Galecto Corporate Management
| Matthew Kronmiller | EVP Officer | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Becker MD | Chief Officer | Profile | |
| Pr MD | Chief Officer | Profile | |
| Ulf Nilsson | CoFounder | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Galecto diversify its offerings? Factors like these will boost the valuation of Galecto. Market participants price Galecto higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Galecto data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Galecto is measured differently than its book value, which is the value of Galecto that is recorded on the company's balance sheet. Investors also form their own opinion of Galecto's value that differs from its market value or its book value, called intrinsic value, which is Galecto's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Galecto's market value can be influenced by many factors that don't directly affect Galecto's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galecto's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galecto is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Galecto's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.